Recent Updates — AZTA
Azenta acquired all outstanding capital stock of SynPlexity, a DNA assembly technology company specializing in large, multiplexed gene libraries for functional screening and drug discovery. The acquisition closed concurrently with the execution of the Stock Purchase Agreement on October 28, 2026. Concurrently, Azenta entered into an exclusive, royalty-free license agreement with Elegen Corp. to access proprietary cell-free DNA manufacturing technology, including patents related to gene synthesis and cell-free cloning. Under the supply arrangement, aggregate capital deployment is expected to range from approximately $32 million to $71 million over five years, contingent on equipment purchases and a potential $25 million option to convert the license to perpetual rights. These strategic investments are intended to enhance Azenta's GENEWIZ gene synthesis capabilities, improve manufacturing scalability, and support regional production expansion. Azenta is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services for drug development and clinical research.
On October 5, 2026, Azenta's Board approved a restructuring plan within its Multiomics segment to consolidate North American laboratory sites and simplify organizational structure. The company estimates aggregate pre-tax charges of approximately $11.0 million to $13.0 million, including roughly $9.0 million in asset impairment and $3.0 million in severance costs. Future cash expenditures are estimated at $7.0 million. Azenta expects to recognize substantially all charges during fiscal 2027 and complete the plan by March 31, 2027, targeting annualized cost savings of approximately $11.0 million. This initiative is separate from earlier restructuring actions completed in August and September 2026 that did not result in material charges. Azenta operates in the life sciences industry, providing sample management solutions and multiomics services.
Azenta, Inc. appointed Dr. Martin D. Madaus as Interim President and CEO effective August 22, 2026, with the Board approving a compensation package on September 14, 2026. The agreement includes a $600,000 annual base salary and a cash performance bonus equal to 100% of base salary, payable January 1, 2028, contingent on continued employment. Madaus also received restricted stock units valued at $1,200,000, vesting monthly over one year. Additionally, the Board approved one-time retention awards for four named executive officers: Lawrence Lin ($1,000,000), Ephraim Starr ($500,000), Olga Pirogova ($500,000), and Trey Martin ($500,000). These awards consist of time-based restricted stock units vesting 50% on the first and second anniversaries of the grant date. The Board also reconstituted its Nominating and Governance Committee. Azenta operates in the life sciences technology sector, providing instruments, consumables, and services for sample management and analysis.
Azenta, Inc. announced the full repayment of a $35 million secured vendor loan extended to Thelema S.à r.l. in connection with the July 1, 2026 sale of its subsidiary B Medical Systems. The borrower repaid the principal plus accrued interest on September 3, 2026, totaling $35,373,333, prior to the loan's maturity. This repayment satisfies all obligations under the Vendor Loan Agreement and releases the share pledge securing the transaction. Consequently, Azenta has now received the entire $63 million purchase price for B Medical Systems in cash, completing the divestiture and eliminating credit exposure associated with the deal. Azenta operates as a provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, and academic institutions globally.
On August 6, 2026, Azenta appointed Erik J. Bello as Vice President and Chief Accounting Officer, effective August 31, 2026. Lawrence Lin will cease serving as principal accounting officer but remains Executive Vice President and Chief Financial Officer. Mr. Bello receives a $380,000 annual base salary, an $80,000 sign-on bonus, and equity grants totaling $450,000 over two years. Azenta operates in the life sciences technology sector, providing instruments, reagents, and services for research and development.
Azenta, Inc. reported financial results for the third quarter ended June 30, 2026, with revenue from continuing operations reaching $161 million, a 12% increase year over year. Organic growth was 9%, driven by Sample Management Solutions ($88 million) and Multiomics ($73 million). The company reported a diluted EPS of $(0.03) from continuing operations and total diluted EPS of $0.05. Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 11.4%. Azenta updated its full-year fiscal 2026 guidance, now expecting total reported revenue between $613 million and $618 million and Adjusted EBITDA between $59 million and $62 million. The company ended the quarter with $529 million in cash and liquidity. As of June 30, 2026, Azenta had repurchased 2.3 million shares for $50 million under its 2025 share repurchase program. Azenta is a provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, and academic institutions.